Related Experiment Videos
Role of platelet-derived growth factor in allograft vasculopathy
1Division of Cardiothoracic Surgery, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71106, USA. mmanci@lsumc.edu
Insights
Platelet-derived growth factor (PDGF) accelerates allograft vasculopathy, a key factor in heart transplant failure. Blocking the PDGF-A receptor significantly reduced coronary artery hyperplasia, suggesting a potential new therapy.
Area of Science:
- Cardiovascular Research
- Transplantation Immunology
- Vascular Biology
Background:
- Allograft vasculopathy, marked by coronary artery myointimal hyperplasia, is a primary cause of late heart transplant failure.
- The underlying mechanisms of allograft vasculopathy remain unclear, and effective treatments are lacking.
- Platelet-derived growth factor (PDGF) is implicated in vascular diseases, but its role in allograft vasculopathy was unexplored.
Purpose of the Study:
- To investigate the role of platelet-derived growth factor (PDGF) in the development of allograft vasculopathy.
- To determine if PDGF accelerates the formation of myointimal hyperplasia in transplanted heart coronary arteries.
Main Methods:
- An orthotopic heart transplant rat model was utilized without immunosuppression.
- Groups received varying doses of PDGF-A, PDGF-A antibody, or PDGF-A receptor antibody.
- Coronary arteries were analyzed morphometrically after 50 days, with smooth muscle proliferation confirmed via immunohistochemistry.
Main Results:
- Significant myointimal hyperplasia was observed in the PDGF-A treated groups.
- PDGF-A antibody administration did not inhibit the hyperplastic process.
- PDGF-A receptor antibody treatment dose-dependently attenuated coronary myointimal hyperplasia.
Conclusions:
- A direct causal link between PDGF-A and coronary myointimal hyperplasia in this rat transplant model was established.
- Blocking the PDGF-A receptor effectively reduces allograft vasculopathy.
- Targeting the PDGF-A receptor presents a promising therapeutic strategy for preventing graft failure in heart transplant recipients.
Objective:
To test the hypothesis that platelet-derived growth factor (PDGF) accelerates the formation of allograft vascular disease.
Summary Background Data:
Allograft vasculopathy, characterized by myointimal hyperplasia of the coronary arteries in the transplanted heart, is the most common cause of late graft failure and death in heart transplant recipients. The cause of the process is unclear, and no treatment exists. PDGF has been implicated in alterations in vascular endothelial biology and in vascular restenosis, but the role of PDGF in allograft vasculopathy has not been explored.
Methods:
An orthotopic heart transplant model was established in the rat mismatched at one class II locus using the PVGR8 and PVGR23 strains. No immunosuppressive regimen was used. Six treatment groups (PDGF-A, PDGF-A antibody, and PDGF-A receptor antibody) using 10 rats per group were examined. An untreated group of 10 rats manifesting chronic rejection as well as the native hearts were used as controls. PDGF-A at 1 ng/dL (10 rats) or 10 ng/dL (10 rats) was administered intraperitoneally to each transplant group. Similar groups were treated with PDGF-A antibody and PDGF-A receptor antibody. The animals were killed after 50 days; transplanted and native hearts were removed and coronary arteries were examined morphometrically. Smooth muscle proliferation was confirmed by immunohistochemistry. Statistical analysis was performed using multivariate analysis of variance.
Results:
Coronary myointimal hyperplasia was seen in the chronic rejection group. The PDGF-A groups showed significant myointimal hyperplasia. Administration of PDGF-A antibody did not attenuate the process. Administration of PDGF-A receptor antibody at 1 ng/dL resulted in reduction of the hyperplasia, and 10 ng/dL significantly attenuated the process.
Conclusions:
This study establishes a cause-and-effect relation between PDGF-A and coronary myointimal hyperplasia in the rat transplant model. Blockade of the PDGF-A receptor clearly attenuates the process, indicating a potential mode of therapy to be explored.